Essential Pharma Acquires Ventavis for Primary Pulmonary Hypertension from Bayer AG
核心洞察
Essential Pharma (搜索) acquired Ventavis (iloprost trometamol (搜索)), an established inhaled prostacyclin analogue for treating primary pulmonary hypertension (搜索), from Bayer AG.
The acquisition includes global rights to Ventavis across all markets except the USA and Russia, plus worldwide rights to the Breelib nebuliser delivery technology.
Ventavis is indicated for adult patients with NYHA functional class III primary pulmonary hypertension (搜索) and is commercially available in over 60 markets globally.
Essential Pharma (搜索), a global specialty pharmaceutical company, announced the acquisition of Ventavis (iloprost trometamol (搜索)) from Bayer AG on February 17, 2026, marking a significant expansion of its rare disease portfolio. The transaction includes rights to the accompanying Breelib nebuliser delivery technology and reinforces the company's mission to serve underserved rare disease populations.
Strategic Acquisition Details
Under the terms of the acquisition, Essential Pharma (搜索) has secured rights to Ventavis across all global markets, excluding the USA and Russia, along with global rights to Breelib. The product is currently commercially available in over 60 markets worldwide, providing Essential with immediate access to an established patient base.
The acquisition represents a strategic milestone as Essential Pharma (搜索) continues to grow its specialty rare disease franchise. The transaction expands the company's commercial presence in rare cardio-pulmonary disease, complementing the acquisition of Colobreathe announced in early 2024.
Therapeutic Profile and Clinical Application
Ventavis is a well-established prostacyclin analogue indicated for adult patients with primary pulmonary hypertension (搜索) classified as NYHA functional class III. Primary pulmonary hypertension is a rare condition characterized by elevated blood pressure in the blood vessels between the heart and the lungs.
The medication is designed to improve exercise capacity and symptoms in affected patients. Ventavis is administered through a nebuliser, such as Breelib, enabling targeted delivery of the drug to the lungs where it can work most effectively. This targeted approach results in improved blood flow, enhanced oxygen supply to the body, and reduced strain on the heart.
Company Leadership Perspective
Simon Ball, President Rare Disease and Interim CEO of Essential Pharma (搜索), emphasized the strategic importance of the acquisition: "Adding Ventavis and the Breelib nebuliser to Essential Pharma's growing rare disease portfolio signals our commitment to enabling continued access to treatments that make a difference to individuals living with niche and rare medical conditions. This acquisition leverages our global commercial footprint and highlights our motivation to invest further into rare diseases, building on our strong reputation as a partner of choice in the biopharmaceutical sector."
Essential Pharma's Rare Disease Focus
Essential Pharma (搜索) operates as a global pharmaceutical company with a mission to develop and deliver medicines for small, underserved, or rare disease populations globally. The company has established a proven track record of acquiring, investing in, and commercialising specialty medicines.
The company's growing product portfolio reaches patients in approximately 70 countries across multiple therapy areas, with particular focus on rare disease, CNS, ophthalmology, and gastroenterology. Essential's investments in rare diseases span rare cardio-pulmonary conditions and rare paediatric oncology, where the company's first development-stage asset is an anti-GD2 antibody for treating high-risk neuroblastoma (搜索).